Skip to content

The effect of noradrenaline infusion versus standard blood pressure management on perioperative HYPotension in NOncaRdiac surgery.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508255-39-00
Acronym
HYP-NOR
Enrollment
750
Registered
2024-07-22
Start date
2025-06-16
Completion date
Unknown
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension in non-cardiac surgery

Brief summary

The primary outcome is perioperative hypotension, defined as any mean arterial pressure (MAP) reading ≤55 mmHg during and up to 4 hours after noncardiac surgery.

Detailed description

Secondary outcomes include time under MAP ≤60 mm Hg intraoperatively and postoperatively; a composite of major perfusion-related complications: myocardial injury after noncardiac surgery (MINS), acute kidney injury (AKI), stroke, non-fatal cardiac arrest, sepsis, and death of all causes; infusion-related reactions; days alive and at home up to 30 days after surgery.

Interventions

DRUGLEVONOR
DRUG1 mg/ml

Sponsors

Uniwersytet Jagiellonski Collegium Medicum
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary outcome is perioperative hypotension, defined as any mean arterial pressure (MAP) reading ≤55 mmHg during and up to 4 hours after noncardiac surgery.

Secondary

MeasureTime frame
Secondary outcomes include time under MAP ≤60 mm Hg intraoperatively and postoperatively; a composite of major perfusion-related complications: myocardial injury after noncardiac surgery (MINS), acute kidney injury (AKI), stroke, non-fatal cardiac arrest, sepsis, and death of all causes; infusion-related reactions; days alive and at home up to 30 days after surgery.

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026